Compare Recursion Pharmaceuticals Inc (RXRX) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Spotify Technology — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Spotify Technology trades at $523.96 (market cap $107.52B). The key difference: Spotify Technology is far larger — about 61.8× Recursion Pharmaceuticals Inc's market cap, and Spotify Technology is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SPOT | |
|---|---|---|
Market Cap | $1.74B | $107.52B |
Sector | Health | Media |
52-Week High | $6.79 | $738.53 |
52-Week Low | $2.84 | $412.75 |
Enterprise Value | $1.26B | $97.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Spotify (SPOT) trades at $528.64, down 2.54% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $524 and resistance at $535. Fundamentally, the company reported strong revenue growth to $17.19B in 2025 and a net income margin of 12.87%, though it missed Q2 2026 EPS estimates. Recent news highlights a $1.5B share repurchase program expansion and initiatives to label AI-generated content.
The outlook for SPOT is supported by robust earnings growth, cash flow generation, and analyst optimism, with a consensus price target of $590.29. However, risks include premium valuation multiples, competitive pressures in audio streaming, and execution challenges in sustaining high growth rates. Investor sentiment remains positive given institutional buy ratings, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
